Navigation Links
Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
Date:3/30/2012

SAN DIEGO, March 30, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced the presentation of results from a post-hoc subgroup analysis of the company's two large Phase 3 trials which demonstrated that cancer patients with Clostridium difficile-associated diarrhea (CDAD) had higher clinical cure rates, better sustained response and lower recurrence when treated with DIFICID® (fidaxomicin) tablets compared to oral vancomycin. The data will be presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The analysis included 153 patients with active cancer who were treated in the two DIFICID Phase 3 studies and who received 8 days or more of treatment with DIFICID or oral vancomycin. In the overall combined population, patients with cancer had significantly lower cure and sustained response rates than patients without cancer. DIFICID was five times more likely than vancomycin to produce a clinical response and three times more likely to lead to a sustained response, while patients treated with vancomycin had a 2.6 fold greater risk of experiencing recurrence. Specifically, DIFICID provided superior response compared to vancomycin across all clinical endpoints studied: clinical response (97.3% vs. 87.5%, 95% CI 1.07-23.98; p=0.041), sustained response (83.6% vs. 61.3%, 95% CI 1.50-6.91; p=0.003) and disease recurrence (14.1% vs. 30.0%, 95% CI 0.16-0.89; p=0.025). Furthermore, cancer patients who were treated with DIFICID in the clinical studies had similar cure, recurrence and sustained response rates as non-cancer patients who received the drug, while cancer patients treated with vancomycin tended to have poorer outcomes than non-cancer patients. The ov
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results
2. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
3. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
4. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
5. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
8. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
9. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
10. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
11. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013  Team Health Holdings ... the largest suppliers of outsourced healthcare professional staffing and ... the United States , today announced ... Annual Deutsche Bank Healthcare Conference held on May 29, ... begin at 8:00 AM eastern time.  Interested investors and ...
(Date:5/22/2013)... N.Y. , May 22, 2013  The Leukemia ... million to Valor Biotherapeutics, LLC, a joint venture ... pre-clinical development, manufacturing, and a Phase I clinical trial ... poor outcomes faced by many patients with indolent lymphomas ... Valor,s protein, IGN002, is a new ...
(Date:5/22/2013)... , May 22, 2013 The new 13-valent ... as the previous version used prior to 2010, the ... Permanente study published today in Vaccine. The ... beginning in 2010 after a series of trials. These ... range of pneumococcal types than the previously used PCV7, ...
Breaking Medicine Technology:Team Health Holdings Inc. to Present at the 38th Annual Deutsche Bank Healthcare Conference 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 2The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 3The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients 4Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4
... Attend ROTH Fall Conference at Maui, Hawaii From September 1 -... -- CHENGDU, China, Aug. 30 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by ...
... 30 Phase 3 safety and efficacy data comparing tapentadol ... in patients with moderate to severe chronic osteoarthritis knee pain ... addition, this study compared oxycodone controlled release (CR) to placebo ... ER vs. Placebo The study demonstrated ...
Cached Medicine Technology:Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6 2Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6 3Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6 4Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6 5Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6 6Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain 2Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain 3Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain 4Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain 5Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain 6Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain 7Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain 8Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain 9
(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Migraines and depression ... new research indicates the combination of the two may ... brain. , , Already aware that people with migraines ... determine if having both conditions together affected total brain ... -- isn,t alarming, study authors said, but needs further ...
(Date:5/22/2013)... York (PRWEB) May 22, 2013 Phelps ... established the Westchester Lung Nodule Center for individuals ... receive lung cancer care. Lung cancer is the deadliest form ... more people in the U.S. die from lung cancer than ... with all cancers, early detection increases survival rates. It ...
(Date:5/22/2013)... Registered Dietitian and Founder of Tatalou Science Nathalie ... a recipe for making energy bars at home. , The ... takes a recipe modified from one recently featured on ... it gets more and more difficult to understand what ingredients ... of the nutrition label continues to grow and consumers are ...
(Date:5/22/2013)... Georgia (PRWEB) May 22, 2013 HR ... event, hosted at the Gwinnett County Fairgrounds, on Friday ... company before, they far surpassed expectations; raising over $6,300 ... corporate sponsor for the event, donating the first $3,000 ... Beesley , challenged the internal staff to match the ...
(Date:5/22/2013)... 2013 Go Classy the Original Nudist ... launch of their newest website http://www.Desire-Mexico.com . The ... minds, Desire Resorts have become the premier Nudist and ... of total liberation while allowing you to enjoy a ... Go Classy Tours / Caribbean-Hideaways. He goes on to ...
Breaking Medicine News(10 mins):Health News:Having Both Migraines, Depression May Mean Smaller Brain 2Health News:Having Both Migraines, Depression May Mean Smaller Brain 3Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 2Health News:Phelps Memorial Hospital Center Establishes The Westchester Lung Nodule Center To Diagnose And Administer Lung Cancer Care 3Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:Go Classy Tours Announces the Launch of Their Newest Website for Desire Resorts Located in Mexico Clothing Optional/Aunaturel Resorts a Lovers Paradise 2
... 26 Nutrisystem, Inc. (Nasdaq: NTRI ), a ... announced a new multi-year alliance with the American Diabetes ... and the public about the importance of weight loss ... the relationship, Nutrisystem will support the Association,s efforts to ...
... WASHINGTON , Oct. 26 America,s ... Ignagni, President and CEO: , "A new government-run plan would underpay ... costs and improve quality. The American people want health care ... , "The divisive debate about a government-run plan is ...
... of severe physical, psychosocial suffering, researchers say , MONDAY, ... World War II, those who were potentially exposed to ... due to physical and mental stress, an Israeli study ... rates in more than 300,000 Israeli Jews who were ...
... But healthy habits can stave off the inevitable declines, research ... in fitness that accompany growing old typically speed up after ... But people can slow the inevitable by staying lean, exercising ... Oct. 26 issue of the Archives of Internal Medicine ...
... doubled risk of GERD, may be linked to mental fallout ... rescue workers can add another illness to the list of ... Zero toxins and the ensuing mental anguish of the tragedy ... shows that 41 percent of World Trade Center responders have ...
... , PLANO, Texas, Oct. 26 Perot Systems Corporation (NYSE: ... an agreement with China Telecommunications Corporation (China Telecom) in which ... information technology (IT) solutions for the healthcare industry in China. ... to develop and go to market with an e-health platform ...
Cached Medicine News:Health News:Nutrisystem and the American Diabetes Association Form a Strategic Alliance to Promote the Importance of Weight Loss for People With Type 2 Diabetes 2Health News:Nutrisystem and the American Diabetes Association Form a Strategic Alliance to Promote the Importance of Weight Loss for People With Type 2 Diabetes 3Health News:AHIP Statement on Government-Run Plan 2Health News:AHIP Statement on Government-Run Plan 3Health News:Exposure to Holocaust May Have Raised Cancer Risks 2Health News:Fitness Fades Fast After 45 2Health News:Fitness Fades Fast After 45 3Health News:World Trade Center Workers Have More Cases of Acid Reflux 2Health News:World Trade Center Workers Have More Cases of Acid Reflux 3Health News:Perot Systems Announces Strategic Alliance With China Telecom 2Health News:Perot Systems Announces Strategic Alliance With China Telecom 3
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
... ASRs* are specifically designed for PCR ... two-color fluorescence detection systems. The NGEN ... detection of mutations associated with cystic ... well as reagents for the detection ...
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
... NGEN-brand ASRs* are specifically designed for ... with two-color fluorescence detection systems. The ... the detection of mutations associated with ... as well as reagents for the ...
Medicine Products: